Matter Bio, co-founded by George Church, partners with scientists to study longevity genes in centenarians and long-lived ...

The XBI has plunged 27% since Donald Trump won the election, leaving the public markets an ugly mess for a biotech industry ...

Roche plans $50B investment in US over 5 years for R&D and manufacturing, including 4 new facilities and expansions, amid ...

AstraZeneca/Daiichi's Enhertu plus Perjeta shows better progression-free survival vs standard care in first-line HER2+ ...

Paul Stoffels joined Galapagos to turn it around three years ago. But after a series of unsuccessful studies, pipeline changes and a bumpy quest into cell therapy, the Belgian biotech's turnaround ...

Invivyd secures $30M loan facility from Silicon Valley Bank in three $10M tranches, ahead of FDA discussions about Covid-19 antibody VYD2311 ...

Chinese biotech HuidaGene reports early success with first CRISPR brain treatment in 9-year-old with MECP2 duplication ...

Alvogen plans to fight a court decision that could significantly delay its ability to bring a generic version of Bausch ...

Superpower raises $30M Series A led by Forerunner to expand health testing service offering blood biomarker analysis and app access for $499/year ...

Gilead's antibody-drug conjugate Trodelvy combined with Merck's Keytruda reduced the risk of disease progression or death in ...

The FDA made two de­ci­sions on Re­gen­eron’s best-sell­ing drugs Fri­day, hand­ing down one ap­proval and one re­jec­tion.

Roivant is changing its strategy for Immunovant roughly a month after its subsidiary decided it wouldn’t take one of its ...